Psychoactive Pharmaceuticals Induce Fish Gene Expression Profiles Associated with Human Idiopathic Autism
We ran this piece with Antidepressants causing Autism in Rats last October,
and now we're getting reports on minnows
Seriously, America, How much more of this Psychiatric Crap are we going to put up with?
In the analysis of the ND sets, seven of 12 sets were up-regulated, with significant enrichment of the set associated with idiopathic autism (Table 4). We also observed enrichment of two disorders with adult onset: a set associated with Parkinson’s and one set associated with MS (but not a second, independent MS set). There was no overlap between the autism set and the Parkinson’s & MS sets; 4 genes occurred in both MS and Parkinson’s sets. No other set associated with human neurological disorders was enriched, including secondary autism sets.
Table 4. Sets associated with human neurological disorders.doi:10.1371/journal.pone.0032917.t004
In the analysis of ASD sets, all 10 sets were up-regulated, with significant enrichment of five of the nine expression-based sets (Table 5). Very few genes are shared among enriched sets. The susceptibility set was not enriched; this is significant because one would not necessarily expect genes that underlie susceptibility to also experience differential expression. Interestingly, one of the strongly enriched sets (Voineagu_Down) was identified by the study authors as genes down-regulated in individuals with autism , while its complementary set (Voineagu_Up) was not enriched. The former set was endowed with an overrepresentation of gene ontology categories associated with synapse function, while the latter had an overrepresentation of categories associated with immune and inflammatory response.
Table 5. Analysis of sets associated with human autism.doi:10.1371/journal.pone.0032917.t005
Normalized enrichment scores (NES; Tables 4, 5) for the examined sets ranged from -1.172 to 1.621 for ND sets (58% up-regulated) and 1.050 to 1.537 for ASD sets (100% up-regulated). While the nominal p-value indicates significance of an NES, that value is somewhat difficult to interpret. For comparison, we analyzed 242 curated gene sets from the Molecular Signatures Database  corresponding to each human cytogenetic band that has at least one gene. In that analysis, 52% of the sets were up-regulated, and NES values ranged from -1.70 to 1.73. Only 5% of scores exceeded an NES of 1.40, and no set passed the false discovery rate (FDR) threshold of 0.25.
The analyses in this report consider mainly the MIX treatment of UPPs. For comparison, we included GSEA analysis results from treatments consisting of the three pharmaceuticals considered individually. As one might expect, those treatments had lower NES values and fewer enriched sets relative to the MIX treatment (Tables 6, 7), although the single-drug NES values involving Parkinson’s were all higher than the MIX treatment NES values.
Table 6. Single drug treatments & ASD sets.doi:10.1371/journal.pone.0032917.t006
Table 7. Single drug treatments & ND sets.doi:10.1371/journal.pone.0032917.t007
We found enrichment of gene sets associated with idiopathic ASD but not of sets involving autism diagnoses secondary to other disorders (Rett and fragile X syndromes) known to be caused by specific mutations. This is significant, because it indicates that enrichment in our treatments involve only idiopathic forms of ASD.
There was no enrichment of other neurological disorders except MS (in one of two sets) and Parkinson’s. This is significant because it indicates that enrichment of the idiopathic ASD set was not simply associated with general neurological processes, pathways or systems generally common to neurological disorders. The MS set has a low NES (<1.40), and a second MS set (see Table 4) is not enriched; therefore, we are not exceedingly confident in describing that set as enriched. The other enriched non-ASD set, Parkinson’s, is more interesting, with a convincing NES and an intriguing potential connection to ASD involving similar phenomenology involving brain dysfunction .
A number of the genes contributing to enrichment of ASD gene sets have been implicated in other recent studies not included in our analysis. For example, Suda et al.  found that relative expression levels of EFNB3, PLXNA4 and ROBO2 were significantly different in individuals with autism than in neurotypical individuals; protein levels of PLXNA4 and ROBO2, but not for EFNB3, were significantly reduced in brains of individuals with autism compared to control brains. In the present study, we found 3 plexin genes (PLXNB1, PLXND1 & PLXNA3; PLXNA4 was not on the array) and ROBO2 to be strongly down-regulated in response to the MIX treatment, while EFNB3 and five related genes (EFNB1, EFNA1, EFNA2, EFNA3 & EFNA5) were up-regulated. These and other genes contributing to gene set enrichment are associated with the formation of synapses, perturbation of which may indicate an altered and imprecise synaptic connections or a failure to form mature neural circuits.
The results presented here are consistent with several recent lines of inquiry: First, the hypothesis that hyperserotonemia plays a role in autism, affecting the developing fetus and potentially involving SSRIs . In that work, Hadjikhani explored a potential role of elevated serotonin levels perturbing brain development during pregnancy (in which he assumes that maternal serotonin ultimately passes the fetal blood brain barrier). The author speculated that elevated levels could be increased by maternal use of serotonin elevating pharmaceuticals (like SSRIs) or consumption of serotonin-rich foods. In the present study, serotonin levels were not measured. However, all six serotonin receptor genes on the array (HTR1A, HTR1B, HTR2C, HTR4, HTR7& SLC6A4) were strongly down-regulated in response to the MIX treatment. If this implies a consequential elevation of serotonin levels, our results would seem to be consistent with the Hadjikhani hypothesis  and with other recent experimental work using model organisms .
Second, recent evidence supports an association of antidepressants, including SSRIs, with autism . In that study, Croen and colleagues found a 2-fold increase in ASD risk associated with SSRIs, with the strongest effect occurring in the first trimester. The results of the present study are consistent with this finding. However, maternal SSRI use is not sufficient to explain the increase in prevalence of ASD.
Third, there is evidence for an unambiguous environmental component involved in the etiology of autism. In that study, Hallmayer and colleagues provide robust evidence that, while having a moderate genetic component, ASD also clearly involves an environmental trigger. The results of the present study are consistent with this finding, as is the assumption that the environmental trigger acts in concert with genetic susceptibility.
Fourth, there is evidence of demographic changes that may have increased the proportion of genetically susceptible individuals in contemporary populations . In that study, Baron-Cohen proposed that assortative mating among genetically susceptible individuals has increased the proportion of susceptible individuals in human populations since the 1970s. Especially when coupled with increased levels of an environmental trigger, this would create circumstances in which one would expect an increase in ASD prevalence. Given that SSRIs were introduced in the mid-1980s and SNRIs in the mid-1990s, coincident with increases in ASD prevalence , the assortative mating hypothesis provides a framework for understanding why such a trigger is able to induce such a large effect. The results of the present study provide a potential source of exposure to psychoactive pharmaceuticals that does not involve maternal clinical usage of SSRIs.
Given the conserved nature (i.e., sequence and function) of the genes involved in the observed expression profiles, and given that the genes on the Fathead array are homologous to highly conserved human genes, it is reasonable to expect induction of humans gene expression profiles similar to the Fathead profiles. This sort of approach has been effectively used for other models of human disorders  and in previous investigations involving the Fathead microarray platform . Here, many of the enriched sets involve genes associated with neuronal development and growth , which is consistent with systems and pathways known to be perturbed in the developing brain of individuals with autism , .
The concentrations used in this study were higher than observed environmental concentrations in order to account for conservative concentration estimates and the presence of related formulations and active metabolites , , , . Future work needs to be conducted to measure the concentrations of all UPP constituents present in aquatic systems and drinking water (with appropriate temporal and geographic sampling) in order to accurately assess human exposure and health consequences.
These results provide a new perspective on the etiology of idiopathic ASD and suggest new directions for research into autism’s environmental “exposome” . The results of the gene expression study indicate that a mixture of UPPs can induce an ASD-like gene expression profile in a model organism. Using a low-cost model system like fathead minnow, researchers can rapidly screen potential teratogens for their ability to induce ASD-like gene expression patterns in developing brains. In order to clearly determine if UPPs are associated with idiopathic ASD in humans, future work needs to examine a wider palette of UPPs (and other potential teratogens) and results need to be validated by demonstrating treatment response in another model systems. This could involve using a mouse model, with which one could measure fetal brain expression patterns, UPP concentration in fetal blood, and concentrations of fetal neurohypophyseal hormones, following maternal treatment. Further, epidemiological studies at the individual patient level should be conducted to confirm and specify the relationship between environmental contaminants and ASDs. The mimicry of ASD-like gene expression profiles in fish, described above, does not conclusively indicate UPP induction of ASD in humans. It does, however, serve as the basis for new hypotheses regarding the etiology of idiopathic ASD.
Materials and Methods Top
All fish handling and treatments were performed at the Great Lakes WATER Institute (School of Freshwater Sciences, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin) using appropriate UWM Institutional Animal Care and Use Committee (IACUC) approved protocols (approval number 0708#14).
Full details of the fish treatments are described in a previous report . Briefly, three 2-gallon tanks were used for each pharmaceutical treatment along with three tanks for a mixture treatment (containing all three pharmaceuticals in the concentrations listed in Table 1) and three tanks for control (containing no pharmaceuticals). Each tank housed five juvenile fathead minnows. Dosages of pharmaceuticals were re-administered with each change of the tank water (every 2 days). Fish were exposed to treatments for eighteen days.
Gene Set Enrichment Analysis
Fish mRNA was pooled within a tank for microarray work (for 3 replicates per treatment) but not for qPCR validation (for 15 replicates per treatment). Details of microarray experiments, including validation by qPCR analysis of 9 genes with high rank correlation and all data files, are described in a previous report . Microarray experiments conformed to MIAME guidelines and results were deposited in GEO (GSE22261).
The previous study  also described an altered phenotype associated with pharmaceutical treatment that involved measuring fish behavior in response to a startle stimulus modeled after predator avoidance behavior used elsewhere . We found that fish behavior was indicative of a neurologically relevant phenotype: following a “startle,” the distance traveled and number of direction changes both significantly increased for treated fish .
Here, two groups of gene sets gene-class analyses were conducted: ND (“neurological disorder”) and ASD (“autism spectrum disorder”). The gene sets in the ND collection, known to be associated with a variety of human neurological disorders, are described in Table 2. The gene sets in the ASD collection, associated with enriched gene expression in autism, are described in Table 3. Both gene sets are provided in Supporting Information (Table S1, “ND gene list,” and Table S2, “ASD gene list”). Each group consisted of a collection of gene sets, with each set tested against the ranked list of genes reflecting signal-to-noise ratio of MIX treatment (combining FLX, VNX & CBZ) relative to control. Additional comparisons between the control and treatments consisting of the three pharmaceuticals considered individually were included for comparison (Tables 6, 7).
Gene-class analyses used GSEA release 2.06 and MSigDB release 2.5. Weighted enrichment scores were calculated using gene expression lists ranked by signal-to-noise ratio. The genes on the array were ranked by correlation between the MIX and CTL treatments (those genes with the strongest up-regulation in treatment relative to control were ranked highest; those with strongest down-regulation were ranked lowest). (See Table S3, “Ranked gene list,” for these data.) The maximum gene set size was set to 500 genes; the minimum gene set size was set to 10 genes; the number of permutations was set to 1000. Permutations were conducted by gene set (rather than by phenotype). For details of GSEA parameter usage, see Subramanian et al. .
Gene sets were examined to ensure they contained only GSEA-recognized primary HUGO symbols, rather than aliases or unapproved symbols. This was accomplished through the use of a custom script that compared each gene in a given set to the GENE_SYMBOLS.chip file (from GSEA) containing a list of HUGO symbols with accepted aliases. Gene set components listed as aliases in this file were replaced with the appropriate HUGO symbol. For additional details of the annotation and GSEA implementation using the EcoArray 15k Fathead Minnow arrays, see Thomas et al. .
Supporting Information TopTable S1.
ND gene list. A list of the neurological disorders gene sets, in the GSEA gene matrix (.GMX) file format.
ASD gene list. A list of the autism spectrum disorders gene sets, in the GSEA gene matrix (.GMX) file format.
Ranked gene list. A Microsoft Excel spreadsheet containing all annotated array gene elements sorted by signal-to-noise ratio for the mixture v. control comparison.
D. Arndt and J. Crago provided support and expertise on lab techniques and fish handling. C. Ryan and E. O’Leary-Jepsen provided critical expertise in support of the qPCR analysis. R. Salmore, P. Hallock, L. Yang, S. St. Hillaire, and G. Kaushik provided feedback on an early draft of the manuscript.
Author Contributions Top
Conceived and designed the experiments: MAT RDK. Performed the experiments: MAT. Analyzed the data: MAT. Contributed reagents/materials/analysis tools: MAT RDK. Wrote the paper: MAT RDK.
- (2010) What causes autism? Exploring the environmental contribution. Current Opinion in Pediatrics 22: 219.225 FIND THIS ARTICLE ONLINE
- (2010) Understanding and Determining the Etiology of Autism. Cellular and Molecular Neurobiology 30: 161.171 FIND THIS ARTICLE ONLINE
- (2009) Update on autism: A review of 1300 reports published in 2008. Epilepsy & Behavior 16: 569.589 FIND THIS ARTICLE ONLINE
- (2010) Functional impact of global rare copy number variation in autism spectrum disorders. Nature 466: 368.372 FIND THIS ARTICLE ONLINE
- (2007) Strong association of de novo copy number mutations with autism. Science 316: 445.449 FIND THIS ARTICLE ONLINE
- (2009) Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature 459: 569.573 FIND THIS ARTICLE ONLINE
- (2011) Genetic Heritability and Shared Environmental Factors Among Twin Pairs With Autism. Arch Gen Psychiatry: archgenpsychiatry.2011.2076.
- (2007) Identification and evaluation of children with autism spectrum disorders. Pediatrics 120: 1183.1215 FIND THIS ARTICLE ONLINE
- (2010) Changes in autism spectrum disorder prevalence in 4 areas of the United States. Disability and Health Journal 3: 186.201 FIND THIS ARTICLE ONLINE
- (2010) Timing of Increased Autistic Disorder Cumulative Incidence. Environmental Science & Technology 44: 2112.2118 FIND THIS ARTICLE ONLINE
- (2009) The Expanded Biology of Serotonin. Annual Review of Medicine 60: 355.366 FIND THIS ARTICLE ONLINE
- (2008) Further studies in the developmental hyperserotonemia model (DHS) of autism: Social, behavioral and peptide changes. Brain Research 1189: 203.214 FIND THIS ARTICLE ONLINE
- (2011) Perinatal antidepressant exposure alters cortical network function in rodents. Proceedings of the National Academy of Sciences of the United States of America 108: 18465.18470 FIND THIS ARTICLE ONLINE
- (2003) Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. Journal of Pediatrics 142: 402.408 FIND THIS ARTICLE ONLINE
- (2010) Use of antidepressants during pregnancy and the risk of spontaneous abortion. Canadian Medical Association Journal 182: 1031.1037 FIND THIS ARTICLE ONLINE
- (2010) Fetal Exposure to Antidepressants and Normal Milestone Development at 6 and 19 Months of Age. Pediatrics 125: E600.E608 FIND THIS ARTICLE ONLINE
- (2010) Treatment of depressed pregnant women by selective serotonin reuptake inhibitors: Risk for the foetus and the newborn. Encephale-Revue De Psychiatrie Clinique Biologique Et Therapeutique 36: D133.D138 FIND THIS ARTICLE ONLINE
- (2010) Neurodevelopmental effects of prenatal exposure to psychotropic medications. Depression and Anxiety 27: 675.686 FIND THIS ARTICLE ONLINE
- (2009) Sustained Neurobehavioral Effects of Exposure to SSRI Antidepressants During Development: Molecular to Clinical Evidence. Clinical Pharmacology & Therapeutics 86: 672.677 FIND THIS ARTICLE ONLINE
- (2010) Prenatal Effects of Selective Serotonin Reuptake Inhibitor Antidepressants, Serotonin Transporter Promoter Genotype (SLC6A4), and Maternal Mood on Child Behavior at 3 Years of Age. Archives of Pediatrics & Adolescent Medicine 164: 444.451FIND THIS ARTICLE ONLINE
- (2011) Antidepressant Use During Pregnancy and Childhood Autism Spectrum Disorders. Arch Gen Psychiatry: archgenpsychiatry.2011.2073.
- (2005) Characteristics of fetal anticonvulsant syndrome associated autistic disorder. Developmental Medicine and Child Neurology 47: 551.555 FIND THIS ARTICLE ONLINE
- (2009) Cognitive abilities and behaviour of children exposed to antiepileptic drugs in utero. Current Opinion in Neurology 22: 162.166 FIND THIS ARTICLE ONLINE
- (2010) Behavior and serotonergic disorders in rats exposed prenatally to valproate: A model for autism. Neuroscience Letters 470: 55.59FIND THIS ARTICLE ONLINE
- (2008) Gender-specific behavioral and immunological alterations in an animal model of autism induced by prenatal exposure to valproic acid. Psychoneuroendocrinology 33: 728.740 FIND THIS ARTICLE ONLINE
- (2008) Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology 71: 1923.1924 FIND THIS ARTICLE ONLINE
- (2010) Serotonin, pregnancy and increased autism prevalence: Is there a link? Medical Hypotheses 74: 880.883 FIND THIS ARTICLE ONLINE
- (2006) Excretion and ecotoxicity of pharmaceutical and personal care products in the environment. Ecotoxicology and Environmental Safety 63: 113.130 FIND THIS ARTICLE ONLINE
- (2010) Ecotoxicological aspects related to the presence of pharmaceuticals in the aquatic environment. Journal of Hazardous Materials 175: 45.95FIND THIS ARTICLE ONLINE
- (2010) Waterborne fluoxetine disrupts feeding and energy metabolism in the goldfish Carassius auratus. Aquatic Toxicology 100: 128.137 FIND THIS ARTICLE ONLINE
- (2009) Human health risk assessment from the presence of human pharmaceuticals in the aquatic environment. Regulatory Toxicology and Pharmacology 53: 39.45 FIND THIS ARTICLE ONLINE
- (2005) Human pharmaceuticals in US surface waters: A human health risk assessment. Regulatory Toxicology and Pharmacology 42: 296.312 FIND THIS ARTICLE ONLINE
- (2010) Antidepressants and their metabolites in municipal wastewater, and downstream exposure in an urban watershed. Environmental Toxicology and Chemistry 29: 79.89 FIND THIS ARTICLE ONLINE
- (2009) Pharmaceutical metabolites in the environment: Analytical challenges and ecological risks. Environmental Toxicology and Chemistry 28: 2473.2484 FIND THIS ARTICLE ONLINE
- (2010) Spatiotemporal distribution of pharmaceuticals in the Douro River estuary (Portugal). Science of the Total Environment 48: 5513.5520 FIND THIS ARTICLE ONLINE
- (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America 102: 15545.15550 FIND THIS ARTICLE ONLINE
- (2011) Gene set enrichment analysis of microarray data from Pimephales promelas (Rafinesque), a non-mammalian model organism. BMC Genomics 12: 66.FIND THIS ARTICLE ONLINE
- (2011) Gene-class analysis of expression patterns induced by psychoactive pharmaceutical exposure in fathead minnow (Pimephales promelas) indicates induction of neuronal systems. Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology 155: 109.120 FIND THIS ARTICLE ONLINE
- (2009) Gene Expression Profiling Differentiates Autism Case-Controls and Phenotypic Variants of Autism Spectrum Disorders: Evidence for Circadian Rhythm Dysfunction in Severe Autism. Autism Research 2: 78.97 FIND THIS ARTICLE ONLINE
- (2011) Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature advance online publication.
- (2009) Neurological considerations: Autism and Parkinson’s disease. Psychiatry Research 170: 43.51 FIND THIS ARTICLE ONLINE
- (2011) Replication study of Japanese cohorts supports the role of STX1A in autism susceptibility. Progress in Neuro-Psychopharmacology & Biological Psychiatry 35: 454.458 FIND THIS ARTICLE ONLINE
- (2006) The hyper-systemizing, assortative mating theory of autism. Progress in Neuro-Psychopharmacology & Biological Psychiatry 30: 865.872 FIND THIS ARTICLE ONLINE
- (2010) Systematic discovery of nonobvious human disease models through orthologous phenotypes. Proceedings of the National Academy of Sciences of the United States of America 107: 6544.6549 FIND THIS ARTICLE ONLINE
- (2011) Fetal exposure to teratogens: Evidence of genes involved in autism. Neuroscience and Biobehavioral Reviews 35: 1254.1265 FIND THIS ARTICLE ONLINE
- (2004) The treatment of depression with different formulations of venlafaxine: a comparative analysis. Human Psychopharmacology-Clinical and Experimental 19: 9.16FIND THIS ARTICLE ONLINE
- (2003) Distribution of acidic and neutral drugs in surface waters near sewage treatment plants in the lower Great Lakes, Canada. Environmental Toxicology and Chemistry 22: 2881.2889 FIND THIS ARTICLE ONLINE
- (2010) Environment and Disease Risks. Science 330: 460.461 FIND THIS ARTICLE ONLINE
- (2009) Antidepressants at environmentally relevant concentrations affect predator avoidance behavior of larval fathead minnows (Pimephales promelas). Environmental Toxicology and Chemistry 28: 2677.2684 FIND THIS ARTICLE ONLINE
- (2008) Analysis of ecologically relevant pharmaceuticals in wastewater and surface water using selective solid-phase extraction and UPLC-MS/MS. Analytical Chemistry 80: 5021.5030 FIND THIS ARTICLE ONLINE
- (2008) Trace analysis of antidepressant pharmaceuticals and their select degradates in aquatic matrixes by LC/ESI/MS/MS. Analytical Chemistry 80: 1756.1762 FIND THIS ARTICLE ONLINE
- (1998) Occurrence of drugs in German sewage treatment plants and rivers. Water Research 32: 3245.3260 FIND THIS ARTICLE ONLINE
- (2006) Pharmaceuticals and endocrine disruptors in wastewater treatment effluents and in the water supply system of Calgary, Alberta, Canada. Water Quality Research Journal of Canada 41: 351.364 FIND THIS ARTICLE ONLINE
- (2010) Presence of pharmaceutically active compounds in Donana Park (Spain) main watersheds. Journal of Hazardous Materials 177: 1159.1162FIND THIS ARTICLE ONLINE
- (2009) Probabilistic environmental risk characterization of pharmaceuticals in sewage treatment plant discharges. Chemosphere 77: 351.358FIND THIS ARTICLE ONLINE
- (2010) Pharmaceuticals in the aquatic environment: A critical review of the evidence for health effects in fish. Critical Reviews in Toxicology 40: 287.304 FIND THIS ARTICLE ONLINE
- (2010) Pollution by psychoactive pharmaceuticals in the Rivers of Madrid metropolitan area (Spain). Environment International 36: 195.201 FIND THIS ARTICLE ONLINE
- (2010) Removal of pharmaceuticals during wastewater treatment and environmental risk assessment using hazard indexes. Environment International 36: 15.26 FIND THIS ARTICLE ONLINE
- (2007) Efficiency of conventional drinking-water-treatment processes in removal of pharmaceuticals and other organic compounds. Science of the Total Environment 377: 255.272 FIND THIS ARTICLE ONLINE
- (2010) Toxicological Relevance of Pharmaceuticals in Drinking Water. Environmental Science & Technology 44: 5619.5626 FIND THIS ARTICLE ONLINE
- (2004) Persistence of pharmaceutical compounds and other organic wastewater contaminants in a conventional drinking-watertreatment plant. Science of the Total Environment 329: 99.113 FIND THIS ARTICLE ONLINE
- (2008) A Comparison of Molecular Alterations in Environmental and Genetic Rat Models of ADHD: A Pilot Study. American Journal of Medical Genetics Part B-Neuropsychiatric Genetics 147B: 1554.1563 FIND THIS ARTICLE ONLINE
- (2002) Gene expression patterns vary in clonal cell cultures from Rett syndrome females with eight different MECP2 mutations. BMC Medical Genetics 3: 12. FIND THIS ARTICLE ONLINE
- (2007) Genome-wide expression profiling of lymphoblastoid cell lines distinguishes different forms of autism and reveals shared pathways. Human Molecular Genetics 16: 1682.1698 FIND THIS ARTICLE ONLINE
- (2010) Proteome analysis of schizophrenia brain tissue. World Journal of Biological Psychiatry 11: 110.120 FIND THIS ARTICLE ONLINE
- (2004) Incipient Alzheimer’s disease: Microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proceedings of the National Academy of Sciences of the United States of America 101: 2173.2178FIND THIS ARTICLE ONLINE
- (2004) Molecular characterization of bipolar disorder by comparing gene expression profiles of postmortem brains of major mental disorders. Molecular Psychiatry 9: 406.416 FIND THIS ARTICLE ONLINE
- (2007) Expression profiling in monozygotic twins discordant for bipolar disorder reveals dysregulation of the WNT signalling pathway. Molecular Psychiatry 12: 815.825 FIND THIS ARTICLE ONLINE
- (2003) Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Human Molecular Genetics 12: 2191.2199 FIND THIS ARTICLE ONLINE
- (2010) Learning from Nature: Pregnancy Changes the Expression of Inflammation-Related Genes in Patients with Multiple Sclerosis. Plos One 5.
- (2009) Genes Related to Sex Steroids, Neural Growth, and Social-Emotional Behavior are Associated with Autistic Traits, Empathy, and Asperger Syndrome. Autism Research 2: 157.177 FIND THIS ARTICLE ONLINE
- (2009) Gene Expression Profiling of Lymphoblasts from Autistic and Nonaffected Sib Pairs: Altered Pathways in Neuronal Development and Steroid Biosynthesis. Plos One 4: 13. FIND THIS ARTICLE ONLINE